Generalized Pustular Psoriasis Clinical Trial
Official title:
CorEvitas Generalized Pustular Psoriasis (GPP) Drug Safety and Effectiveness Registry
Prospective, observational registry for subjects with GPP under the care of a dermatology investigator.Approximately 200 subjects and 75 clinical sites in North America will be recruited to participate with no defined upper limit for either target
The objective of the registry is to obtain information on the treatment patterns, disease activity progression, and the development of comorbidities and adverse events in a cohort of patients with GPP. Data collected will be used to better characterize the natural history and longitudinal trajectory of the disease. This will be done through the standardized data collection including validated patient-reported outcomes (PRO) and clinician-reported outcomes (ClinRO), the active evaluation of prevalent and incident comorbidities and adverse events, and the recording of medication utilization patterns. Personal information is also collected from each consenting registry subject allowing for linkages to other public or private clinical and administrative databases, as well as to databases maintained by organizations focused on the care and treatment of GPP for the purposes of clinical, market, or outcomes research. This provides an opportunity to evaluate other aspects of the disease and its treatment, including but not limited to clinical and drug cost-effectiveness, health care resource utilization, and subject adherence. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT06013969 -
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
|
Phase 4 | |
| Completed |
NCT05512598 -
HB0034 in Patients With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Active, not recruiting |
NCT03886246 -
Effisayil™ ON: A Study to Test Long-term Treatment With Spesolimab in People With Generalized Pustular Psoriasis Who Took Part in a Previous Study
|
Phase 2 | |
| Recruiting |
NCT05670821 -
PMS of Spesolimab I.V. in GPP Patients With Acute Symptoms
|
||
| Recruiting |
NCT06323356 -
A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05239039 -
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Completed |
NCT04399837 -
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
|
Phase 2 | |
| Not yet recruiting |
NCT06433531 -
A Clinical Study of TQH2929 Injection in Treatment With Generalized Pustular Psoriasis (GPP)
|
Phase 1 | |
| Completed |
NCT03942042 -
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
|
Phase 4 | |
| Completed |
NCT06391996 -
Biologic Therapy for Generalized Pustular Psoriasis
|
||
| Completed |
NCT03782792 -
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
|
Phase 2 | |
| Completed |
NCT03619902 -
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
|
Phase 2 | |
| Active, not recruiting |
NCT04566471 -
Palmoplantar Pustulosis and Generalized Pustular Psoriasis: A National Population-based Analysis of Prevalence
|
||
| Recruiting |
NCT06295692 -
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
|
Phase 3 | |
| Completed |
NCT05200247 -
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
|
Phase 3 | |
| Active, not recruiting |
NCT05366855 -
Long-Term Safety and Efficacy of Imsidolimab (ANB019) in Subjects With Generalized Pustular Psoriasis
|
Phase 3 | |
| Completed |
NCT05352893 -
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
|
Phase 3 |